Trials / Completed
CompletedNCT03707106
Benefits of a Cognitive Behavioral Therapy Intervention for Smoking Cessation Supported by Virtual Reality Smoking Cue Exposure
An Efficacy Study Using an Established Cognitive Behavioral Therapy Manual for Smoking Cessation Comparing the Benefit of Virtual Reality Cue Exposure to a Specific Stress Reduction Protocol for Relapse Prevention
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 246 (actual)
- Sponsor
- University Hospital Tuebingen · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Cognitive-behavioral therapy (CBT) combined with medication is an established intervention for smoking cessation. However, long-term abstinence rates of maximum 35% are yielded. Moreover, acceptance of drug treatment is partly very low. Professional recommendation of drug treatment besides nicotine-replacement aids is restrained considering side effects and contraindications. Currently, cue exposure is highly discussed as intervention for craving reduction supporting CBT. There is evidence for benefits of cue exposure optimizing smoking cessation outcomes, as well as evidence for efficacy of exposure in virtual reality (VR) up to date. However, this is the first randomized controlled study focusing on efficacy increases by VR cue exposure supporting an established CBT smoking cessation manual. The control group receives a specific stress reduction treatment (independent of smoking cues), namely, the Progressive Muscle Relaxation (PMR, according to Jacobson) additionally to the established smoking cessation CBT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | CBT smoking cessation | an established protocol for smoking cessation based on cognitive behavioral therapy |
| BEHAVIORAL | virtual reality based cue exposure | smoking cue exposure in virtual reality |
| BEHAVIORAL | progressive muscle relaxation | Progressive muscle relaxation for unspecific stress reduction |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2021-07-02
- Completion
- 2021-07-02
- First posted
- 2018-10-16
- Last updated
- 2023-12-05
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT03707106. Inclusion in this directory is not an endorsement.